[Management of hyperphosphatemia ; phosphate-binder]

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Context:

• Patients with chronic kidney disease (CKD) exhibit significantly increased cardiovascular mortality.
• Hyperphosphatemia is a prevalent and serious complication in advanced CKD.
• Traditional phosphate binders, like calcium carbonate, pose risks including increased calcium load and calcification.

Purpose:

• To evaluate sevelamer as a calcium-free, non-absorbed phosphate binder in CKD patients.
• To assess sevelamer's efficacy in controlling serum phosphorus levels.
• To explore sevelamer's potential benefits beyond phosphorus binding, such as reducing calcification and improving lipid profiles.

Summary:

• Sevelamer is a novel, non-absorbed, calcium-free, and metal-free phosphate binder.
• Clinical studies demonstrate sevelamer's effectiveness in managing hyperphosphatemia in CKD patients.
• Evidence suggests sevelamer may attenuate vascular calcification and positively influence lipid metabolism and inflammation.

Impact:

• Sevelamer offers a safer alternative to calcium-based binders for managing hyperphosphatemia in CKD.
• Potential reduction in cardiovascular and soft tissue calcification may improve patient outcomes.
• Further research into sevelamer's pleiotropic effects could lead to improved CKD management strategies.